Delivery Order SPE2DE24D0013-SPE2D626F48N7
- Not listed
- On December 10, 2025, the Defense Logistics Agency Medical Supply Chain awarded a $4,080 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) for diagnostic testing supplies related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The delivery order, valued at the ceiling amount, has an ultimate completion date of December 17, 2025, and will be performed at Cepheid's headquarters in Sunnyvale, California. This award includes no set-aside designation and...
- The U.S. Defense Logistics Agency, through its Medical Supply Chain division, awarded a $3,638 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on May 30, 2025, with an ultimate completion date of June 13, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, carries no set-aside designation and is for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus detection. The work will be performed at Cepheid's facility in...
- The Defense Department's Medical Supply Chain awarded a $57.8K firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on September 8, 2025, for molecular diagnostic solutions with an ultimate completion date of September 15, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, will be performed in Sunnyvale, California, where Cepheid manufactures its GeneXpert diagnostic systems and associated test kits. This award carries no set-aside designation and represents a continuation of...
- The U.S. Defense Department's Medical Supply Chain agency awarded a $12,040 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 21, 2025, with completion expected by August 28, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, does not utilize a set-aside designation and will be performed at Cepheid's facility in Sunnyvale, California. The award supports the federal government's diagnostic testing capabilities through Cepheid's molecular diagnostic solutions,...
- The U.S. Defense Medical Supply Chain awarded a firm fixed-price delivery order valued at $10,200 to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 15, 2025, with completion scheduled for August 22, 2025. The delivery order, designated 4569128836 for XPCOV2/FLU/RSV-10 diagnostic solutions, carries no set-aside designation and will be performed at Cepheid's Sunnyvale, California facility. This award represents procurement of molecular diagnostic testing capabilities, specifically for detection of...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a $17,000 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 19, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus testing. The contract, designated as XPCOV2/FLU/RSV-10, has an ultimate completion date of August 26, 2025, and will be performed at Cepheid's headquarters in Sunnyvale, California. No small business set-aside was utilized for...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $3,580 to Cepheid Inc. (UEI: W6HQTMWB9Q28) for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The firm fixed-price delivery order, issued on August 7, 2025, is scheduled for completion by August 14, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. This award carries no set-aside designation, indicating it was...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $2,040 to Cepheid Inc. (UEI: W6HQTMWB9Q28) on September 17, 2025, with an ultimate completion date of September 24, 2025. This firm fixed-price delivery order, designated XPCOV2/FLU/RSV-10, carries no set-aside provisions and will be performed at Cepheid's facility in Sunnyvale, California. The contract designation references diagnostic testing for COVID-19, influenza, and respiratory syncytial...
- The Defense Logistics Agency Medical Supply Chain awarded a $8,640 delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on December 2, 2025, with an ultimate completion date of December 9, 2025. This firm fixed-price delivery order, designated XPRS4PLEX-10, contains no set-aside provisions and represents work to be performed at Cepheid's headquarters location in Sunnyvale, California. The contract involves the supply of diagnostic reagents and test kits for Cepheid's GeneXpert platform, which...
- The Defense Logistics Agency's Medical Supply Chain division awarded a $12,694.80 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on September 9, 2025, for molecular diagnostic testing solutions. The delivery order, designated XPCOV2/FLU/RSV-10, is scheduled for completion by September 16, 2025, and will be performed at Cepheid's Sunnyvale, California facility. This award carries no set-aside designation and represents a routine procurement under the company's existing...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D626F48N7Delivery Order
On December 22, 2025, the Defense Logistics Agency Medical Supply Chain awarded a $40,800 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) for respiratory pathogen diagnostic reagents and test kits under contract 4570341774. The delivery order, designated XPCOV2/FLU/RSV-10, supports molecular diagnostic testing capabilities for COVID-19, influenza, and respiratory syncytial virus detection, with an ultimate completion date of December 30, 2025. The award carries no set-aside designation and will be performed at Cepheid's headquarters location in Sunnyvale, California. This delivery order is issued under one of Cepheid's two substantial Indefinite Delivery Contracts with the Department of Veterans Affairs, specifically the VISN 17 single-award IDC valued at $6,741,574.26 through December 28, 2029, which establishes the framework for ongoing procurement of diagnostic reagents and test kits for the GeneXpert diagnostic platform. Cepheid has established itself as a primary federal supplier of molecular diagnostic solutions across multiple agencies including the Veterans Health Administration, Defense Health Agency, Indian Health Service, and U.S. Coast Guard, leveraging its GeneXpert platform expertise to support federal healthcare operations and infectious disease surveillance capabilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.8k | 12/21/25 |